Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Letter to the Editor

The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia

Authors: Andreia Maria Camargos Rocha, Cláudia Souza, Gifone Aguiar Rocha, Fabrício Freire de Melo, Nelma Cristina Diogo Clementino, Marília Campos Abreu Marino, Dulciene Maria Magalhães Queiroz

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

The definition of immune Thrombocytopenia (ITP) as a peripheral blood platelet count less than 100 × 109/L instead of the historical criteria of 150 × 109/L renders subjects with platelets between 100 and 150 × 109/L without a diagnosis. Here, we demonstrated that these subjects have enhanced levels of proinflammatory cytokines linked to Th1 and Th17 cell response, and are more frequently carriers of polymorphisms in genes that code cytokines involved in the commitment of Th1 and Th17 immune response, when compared with controls, similarly to that observed in patients with ITP.
Appendix
Available only for authorised users
Literature
1.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter D: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010, 115: 168-186. 10.1182/blood-2009-06-225565.CrossRefPubMed
2.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report form an international working group. Blood. 2009, 113: 2386-2393. 10.1182/blood-2008-07-162503.CrossRefPubMed
3.
Stasi R, Amadori S, Osborn J, Newland AC, Provan D: Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. Plos Medicine. 2006, 3: 388-394.
4.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011, 117: 4190-4207. 10.1182/blood-2010-08-302984.CrossRefPubMed
5.
Grace RF, Long M, Kalish LA, Neufeld EJ: Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer. 2012, 58: 216-220. 10.1002/pbc.23112.PubMedCentralCrossRefPubMed
6.
Rocha AMC, Souza C, Rocha GA, Melo FF, Clementino NCD, Marino MCA, Bozzi A, Silva ML, Martins-Filho OA, Queiroz DMM: The levels of IL-17A and of the cytokines involved in the Th17 cell commitment are increased in patients with chronic Immune Thrombocytopenia. Haematologica. 2011, 96: 1560-1564. 10.3324/haematol.2011.046417.PubMedCentralCrossRefPubMed
7.
Rocha AMC, Souza C, Rocha GA, Melo FF, Saraiva ISB, Clementino NCD, Marino MCA, Queiroz DMM: IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. Br J Haematol. 2010, 150: 679-684. 10.1111/j.1365-2141.2010.08318.x.CrossRefPubMed
Metadata
Title
The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia
Authors
Andreia Maria Camargos Rocha
Cláudia Souza
Gifone Aguiar Rocha
Fabrício Freire de Melo
Nelma Cristina Diogo Clementino
Marília Campos Abreu Marino
Dulciene Maria Magalhães Queiroz
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-28

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Research

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Review

Biomarkers for determining the prognosis in chronic myelogenous leukemia

Research

Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor

Research

TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity

Research

Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation

Research

Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits